Breaking News

Synchrony Financial Opens at $23/Share, IPO Priced at $23
Tweet TWEET

TherapeuticsMD Announces Trading of Its Common Stock on the NYSE MKT Under Symbol “TXMD”

  TherapeuticsMD Announces Trading of Its Common Stock on the NYSE MKT Under
  Symbol “TXMD”

Business Wire

BOCA RATON, Fla. -- April 22, 2013

TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that its common stock has
been approved for listing on the NYSE MKT, the premier U.S. equities market
for listing and trading of small growth companies. Trading is expected to
commence on the NYSE MKT on Tuesday, April 23, 2013, under the ticker symbol
“TXMD”.

“Becoming a NYSE MKT-listed company will provide enhanced trading liquidity
for current and future shareholders while enabling us to attract a broader
investor base. We view this as significant step in the development of our
company,” stated Rob Finizio, Chief Executive Officer and co-founder of
TherapeuticsMD.

“We are pleased to welcome TherapeuticsMD to the NYSE MKT family of listed
companies,” said Scott Cutler, EVP and Co-Head of U.S. Listings and Cash
Execution at NYSE Euronext. “TXMD will be joining other growth-oriented
companies in the U.S. taking advantage of the NYSE’s advanced and innovative
market model to offer a premier value for listing and trading their stocks.”

About TherapeuticsMD

TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women. The
Company manufactures and distributes branded and generic prescription prenatal
vitamins as well as over-the-counter vitamins and cosmetics. The Company is
currently conducting clinical trials necessary for regulatory approval and
commercialization of advanced hormone therapy pharmaceutical products designed
to alleviate the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding TherapeuticsMD’s
expectations with respect to the timing of the Company’s listing on the NYSE
MKT and beliefs that becoming a NYSE MKT-listed company will provide enhanced
trading liquidity for current and future shareholders while enabling it to
attract a broader investor base and is a significant step in its development,
are forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties that may
cause actual results to differ materially, including but not limited to: the
risks and uncertainties associated with economic and market conditions; risks
and uncertainties associated with TherapeuticsMD’s business and finances in
general; and other risks detailed in TherapeuticsMD’s annual report on Form
10-K filed with the SEC on March 12, 2013, current report on Form 8-K filed
with the SEC on January 25, 2013, and other filings with the SEC. These
forward-looking statements are based on current information that may change.
Investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and TherapeuticsMD undertakes no obligation to revise or update any
forward-looking statement to reflect events or circumstances after the
issuance of this press release.

Contact:

TherapeuticsMD, Inc.
Daniel A. Cartwright, 561-961-1911
Chief Financial Officer
dan.cartwright@therapeuticsmd.com
or
In-Site Communications, Inc.
Lisa M. Wilson, 917-543-9932
Healthcare Investor Relations
lwilson@insitecony.com